Video Home Visits for Dietary Counselling
Optimizing Dietary Habits for Kidney Stone Formers Using Telehealth Directed Individualized Nutritional Counseling
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
This pilot study aims to develop a protocol for home video informed dietary counseling with the goal of reducing overall sodium consumption among kidney stone formers. To accomplish this the investigators will: 1)Assess which data available on video visits are most informative to convey patient sodium consumption, and 2) Administer virtual home visits with informed dietary counseling in our intervention arm and compare this to standard dietary counseling looking specifically at the outcome of 24-hour urine sodium excretion results over time. This study will benefit dramatically from the rapid growth of telehealth medical visits as a consequence of the SARS-CoV-2 pandemic, with the ultimate goal to improve and adapt patient dietary counseling for the prevention of kidney stone disease in the new and evolving era of telehealth.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2027
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 12, 2020
CompletedFirst Posted
Study publicly available on registry
November 18, 2020
CompletedStudy Start
First participant enrolled
July 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2029
Study Completion
Last participant's last visit for all outcomes
June 30, 2029
February 2, 2026
January 1, 2026
2 years
November 12, 2020
January 29, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Urinary sodium
24hr urinary sodium, mean change in mmol/24hrs of excreted urinary sodium from baseline over 24 weeks (Three time points will be recorded: baseline, after 12 weeks, after 24 weeks. Outcome will be mean change from baseline. We will take the average of change from baseline at 12 weeks and change from baseline at 24 weeks)
baseline, 12 weeks, 24 weeks
Secondary Outcomes (2)
Food Frequency Questionnaire (FFQ)
baseline, 12 weeks, 24 weeks
Short Sodium Knowledge Survey (SKSS)
baseline, 12 weeks, 24 weeks
Study Arms (2)
Intervention
EXPERIMENTALThese participants will get virtual home visits with the urologist and dietitian
Control
NO INTERVENTIONThese participants will get standard urologist and dietitian counseling
Interventions
These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
Eligibility Criteria
You may qualify if:
- Patients known to have a history of calcium-based kidney stone disease verified by stone analysis (stones containing calcium oxalate(CaOx) or calcium phosphate(CaP) on stone analysis), or patients with a diagnosis of kidney stone disease verified by imaging (computerized tomography, ultrasound, or plain film/x-ray) and a prior 24-hour urine results with elevated SS CaOx\>8 or SS CaP\>1.25.
- Patients 18 years or older.
- Patients with a smartphone, internet capable tablet, or video capable laptop.
- Patients with a household member with a smartphone, internet capable tablet, or video capable laptop.
You may not qualify if:
- Pregnant patients.
- Patients unable to produce a urine sample.
- Patients who have previous surgical reconstruction involving incorporation of bowel in the urinary tract.
- Patients with known sodium regulation abnormalities (adrenal tumors, pituitary tumors, glucocorticoid deficiency, hypothyroidism, syndrome of inappropriate antidiuretic hormone secretion, nephrotic syndrome, severe congestive heart failure, severe hepatic impairment, etc.).
- Patients on medications significantly affecting urinary sodium levels (lithium, amphotericin, vasopressin V2-receptor antagonists, lactulose, for example).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Bayne, MD, MPH
University of California, San Francisco
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 12, 2020
First Posted
November 18, 2020
Study Start (Estimated)
July 1, 2027
Primary Completion (Estimated)
June 30, 2029
Study Completion (Estimated)
June 30, 2029
Last Updated
February 2, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
The investigators will not share IPD